Jump to content

Mondobiotech

From Wikipedia, the free encyclopedia
Mondobiotech
Company typePublic
IndustryPharmaceutical
Founded2000
Defunct2016
SuccessorRelief Therapeutics
HeadquartersStans, Switzerland

Mondobiotech was a Swiss-based biotechnology company focused on developing human peptides as medicaments for patients affected by rare diseases.

History

[edit]

Mondobiotech was founded in 2000 by Fabio Cavalli and Dorian Bevec.[1] The company listed on the Zurich exchange in 2009.[2] In March 2012, Pharma Times in exclusive negotiations with Pierrel Research, the contact research division of the Italian company Pierrel.[3]

Research and development

[edit]

Mondobiotech created drugs for rare diseases.

Achievements

[edit]
  • Winner of the Swiss Life Sciences Prize 2005.
  • Selected Technology Pioneer 2008 by The World Economic Forum.

Notes and references

[edit]
  1. ^ "Mondobiotech". Archived from the original on 2012-07-20. Retrieved 2012-02-29.
  2. ^ "Swiss Mondobiotech to list on Zurich exchange". Reuters. August 26, 2009. Retrieved November 5, 2021.
  3. ^ Mansell, Peter (6 March 2012). "Pierrel in negotiations for mondoBIOTECH merger". Pharma Times. Retrieved 9 March 2015.

See also

[edit]